Search by :

 

 
Syzygy - July 2010 16-07-2010
Syzygy
What a difference a year makes - This time last year, life was dominated by the appearance of pandemic h 1n 1 influenza a 2009. Travel was restricted, cruise ships were refused docking, major sports functions were under threat, schools and childcare centres were being temporarily closed, and fever clinics were being planned.
Syzygy - August 2010 31-08-2010
Syzygy
We launch our new Womens Health web site.
Our new health information web site goes live this month. First up and running is Women's Health.
Syzygy - Nov-Dec 2010 01-12-2010
Syzygy
Laboratory Diagnosis of Dengue Infections - SNP adds early diagnosis marker NS1 to dengue test panel.
Syzygy - April 2011 07-04-2011
Syzygy
Sullivan Nicolaides now offers a Pap Smear Clinical Audit
Syzygy - May 2011 17-06-2011
Syzygy

Vitamin D plays a significant role in our health and wellbeing.

Syzygy - June July 2011 25-07-2011
Syzygy
This edition of Syzygy focuses on Allergies.
Syzygy September 2011 08-09-2011
Syzygy

SNP have recently changed their 24-hour urine bottles (without preservatives), and we would like to introduce the new Haemolytic Index.

Did you know that there is now a Medicare rebate available for CGH Microarray testing?

SNP Antibiogram - Respiratory Pathogens 10-10-2011
Doctor Bulletins

Sullivan Nicolaides Pathology - Respiratory Pathogens 2004 - 2010 comparison - Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis

Syzygy October 2011 27-10-2011
Syzygy

In this edition of Syzygy, Sullivan Nicolaides Pathology introduces the new, improved testing method for human papillomavirus (HPV). The Roche Cobas 4800 HPV test utilises PCR technology and has performance characteristics comparable to the previously used Hybrid Capture 2 test for the detection of high-grade squamous intraepithelial lesions (HSIL) and cancer of the cervix - but with added advantages.

Sullivan Nicolaides Pathology also introduces the new B-Trace Protein test for the detection of Cerebrospinal Fluid (CSF) leakage.

High risk HPV Test 10-11-2011
Doctor Bulletins

Earlier disease detection - Improved patient management

There is now overwhelming scientific evidence that human papillomavirus (HPV) infection is the major factor in the development of cervical cancer and its precursor lesions. There are, however, many different genotypes of HPV and only some of these have been shown to be associated with the development of high-grade cervical lesions. HPV 16 and 18 are associated with about 70% of cervical cancers and are the types targeted by the HPV vaccine.

Page 2 of 15
<<first | prev | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 | next | last>>